These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 21157438)
1. DAI (DLM-1/ZBP1) as a genetic adjuvant for DNA vaccines that promotes effective antitumor CTL immunity. Lladser A; Mougiakakos D; Tufvesson H; Ligtenberg MA; Quest AF; Kiessling R; Ljungberg K Mol Ther; 2011 Mar; 19(3):594-601. PubMed ID: 21157438 [TBL] [Abstract][Full Text] [Related]
2. NF-κB activation during intradermal DNA vaccination is essential for eliciting tumor protective antigen-specific CTL responses. Ligtenberg MA; Rojas-Colonelli N; Kiessling R; Lladser A Hum Vaccin Immunother; 2013 Oct; 9(10):2189-95. PubMed ID: 23884215 [TBL] [Abstract][Full Text] [Related]
3. A short hairpin RNA-based adjuvant targeting NF-κB repressor IκBα promotes migration of dermal dendritic cells to draining lymph nodes and antitumor CTL responses induced by DNA vaccination. Gálvez-Cancino F; Roco J; Rojas-Colonelli N; Flores C; Murgas P; Cruz-Gómez S; Oyarce C; Varas-Godoy M; Sauma D; Lladser A Vaccine; 2017 Jul; 35(33):4148-4154. PubMed ID: 28666759 [TBL] [Abstract][Full Text] [Related]
4. Intradermal DNA electroporation induces survivin-specific CTLs, suppresses angiogenesis and confers protection against mouse melanoma. Lladser A; Ljungberg K; Tufvesson H; Tazzari M; Roos AK; Quest AF; Kiessling R Cancer Immunol Immunother; 2010 Jan; 59(1):81-92. PubMed ID: 19526360 [TBL] [Abstract][Full Text] [Related]
5. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Davila E; Kennedy R; Celis E Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660 [TBL] [Abstract][Full Text] [Related]
6. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta. Jia ZC; Zou LY; Ni B; Wan Y; Zhou W; Lv YB; Geng M; Wu YZ Cancer Immunol Immunother; 2005 May; 54(5):446-52. PubMed ID: 15750831 [TBL] [Abstract][Full Text] [Related]
7. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein. Zhang M; Ishii K; Hisaeda H; Murata S; Chiba T; Tanaka K; Li Y; Obata C; Furue M; Himeno K Immunology; 2004 Aug; 112(4):567-74. PubMed ID: 15270727 [TBL] [Abstract][Full Text] [Related]
8. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917 [TBL] [Abstract][Full Text] [Related]
9. PolyI:C and mouse survivin artificially embedding human 2B peptide induce a CD4+ T cell response to autologous survivin in HLA-A*2402 transgenic mice. Kasamatsu J; Takahashi S; Azuma M; Matsumoto M; Morii-Sakai A; Imamura M; Teshima T; Takahashi A; Hirohashi Y; Torigoe T; Sato N; Seya T Immunobiology; 2015 Jan; 220(1):74-82. PubMed ID: 25257859 [TBL] [Abstract][Full Text] [Related]
10. Enhancement of immunity by a DNA melanoma vaccine against TRP2 with CCL21 as an adjuvant. Yamano T; Kaneda Y; Huang S; Hiramatsu SH; Hoon DS Mol Ther; 2006 Jan; 13(1):194-202. PubMed ID: 16112911 [TBL] [Abstract][Full Text] [Related]
11. The roles of MHC class II, CD40, and B7 costimulation in CTL induction by plasmid DNA. Chan K; Lee DJ; Schubert A; Tang CM; Crain B; Schoenberger SP; Corr M J Immunol; 2001 Mar; 166(5):3061-6. PubMed ID: 11207256 [TBL] [Abstract][Full Text] [Related]
12. Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2(180-188)-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2(180-188) peptides. Sin JI; Park JB; Lee IH; Park D; Choi YS; Choe J; Celis E Cancer Immunol Immunother; 2012 Oct; 61(10):1671-82. PubMed ID: 22382361 [TBL] [Abstract][Full Text] [Related]
13. Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Saenger YM; Li Y; Chiou KC; Chan B; Rizzuto G; Terzulli SL; Merghoub T; Houghton AN; Wolchok JD Cancer Res; 2008 Dec; 68(23):9884-91. PubMed ID: 19047169 [TBL] [Abstract][Full Text] [Related]
14. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Zhang H; Liu C; Zhang F; Geng F; Xia Q; Lu Z; Xu P; Xie Y; Wu H; Yu B; Wu J; Yu X; Kong W Vaccine; 2016 May; 34(24):2648-55. PubMed ID: 27113167 [TBL] [Abstract][Full Text] [Related]
15. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070 [TBL] [Abstract][Full Text] [Related]
16. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells. Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434 [TBL] [Abstract][Full Text] [Related]
17. Functional equivalency of B7-1 and B7-2 for costimulating plasmid DNA vaccine-elicited CTL responses. Santra S; Barouch DH; Jackson SS; Kuroda MJ; Schmitz JE; Lifton MA; Sharpe AH; Letvin NL J Immunol; 2000 Dec; 165(12):6791-5. PubMed ID: 11120800 [TBL] [Abstract][Full Text] [Related]
18. Plasmid DNA vaccines are effective in the absence of IFNgamma. Hassett DE; Zhang J; Whitton JL Virology; 1999 Oct; 263(1):175-83. PubMed ID: 10544092 [TBL] [Abstract][Full Text] [Related]
19. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model. Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402 [TBL] [Abstract][Full Text] [Related]
20. DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. Rice J; Elliott T; Buchan S; Stevenson FK J Immunol; 2001 Aug; 167(3):1558-65. PubMed ID: 11466377 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]